Regeneron, Sanofi announce Dupixent sBLA accepted for priority review by FDA
Regeneron (REGN) and Sanofi (SNY) announced that the FDA has accepted for priority review the supplemental biologics license application for ...
Law Society of Ireland23h
Sign o’ the times
The type of e-signature methodology an organisation should introduce will depend on a range of factors, and it may be the case that different types of signatures are more appropriate in different ...